Conditions: Cardiomyopathy Chest Pain Dyspnea
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 28
Healthy volunteers: no

Brief summary:
Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and shortness of breath despite conventional medical therapy and/or revascularization. The purpose of this study is to determine the efficacy of taking Ranexa versus placebo in patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional medical therapy and/or percutaneous revascularization.

Detailed description:

Arms:
arm 1: 1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily. arm 2: 1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.

Interventions: intervention 1: Ranexa intervention 2: Placebo
Intervention descriptions: intervention 1: 1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily. intervention 2: 1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.

Protocol document: